Navigation Links
Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
Date:5/20/2008

SEATTLE, May 20 /PRNewswire-FirstCall/ -- Omeros Corporation today announced that it has begun patient enrollment for the Phase 1 study of OMS201, the Company's second PharmacoSurgery(TM) drug product candidate, for use during urological surgery. At least 24 patients undergoing unilateral ureteroscopic removal of stones with a maximum diameter of 12 mm located in the renal-collecting system or ureter will be enrolled in the study.

"Advancing another PharmacoSurgery(TM) product candidate into clinical development marks an important milestone for Omeros," said Dr. Gregory A. Demopulos, Chairman and Chief Executive Officer of Omeros. "From our PharmacoSurgery(TM) platform, Omeros is developing a series of product candidates to improve clinical outcomes for surgical patients. The study for OMS201 expands our PharmacoSurgery(TM) platform into urological surgery."

OMS201 is one of the four clinical development programs in the Company's PharmacoSurgery(TM) platform. PharmacoSurgery(TM) product candidates are combinations of therapeutic agents designed to act simultaneously at multiple discrete targets to preemptively block the molecular-signaling and biochemical cascade caused by surgical trauma and to provide clinical benefits both during and after surgery. The lead product candidate in the PharmacoSurgery(TM) platform is OMS103HP, which is currently in two Phase 3 clinical programs evaluating OMS103HP's safety and ability to improve postoperative joint function and reduce pain following arthroscopic surgery.

The Phase 1 randomized, double-blind, vehicle-controlled and parallel-assigned study of OMS201 is designed to evaluate the systemic absorption and safety of OMS201 in patients receiving primary treatment by endoscopic removal of urinary stones. OMS201, developed from Omeros' proprietary PharmacoSurgery(TM) platform, is designed for use during urological surgery, including uroendoscopic procedures such as ureteroscopy, cystoscopy and minimally invasive prostate procedures. Added to standard irrigation solutions in urological surgery, OMS201 is delivered during the operation directly to the surgical site to inhibit surgically induced inflammation, pain and smooth muscle spasm.

Principal Investigators are Ralph Clayman, MD, Chair of the Department of Urology at University of California Irvine, and Margaret Pearle, MD, PhD, Professor of Urology at University of Texas Southwestern.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.


'/>"/>
SOURCE Omeros Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
2. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
3. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
4. TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
5. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
6. GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
9. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
10. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
11. Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017 A new ... Disinfector™ is the proven ultraviolet-C (UV-C) disinfection solution ... infections (HAIs). Published in the ... Infection Control , the peer-reviewed study of UV-C ... of Vancouver General Hospital and Rochester General Hospital. ...
(Date:3/22/2017)... -- FinancialBuzz.com News Commentary  ... According to a report by the New Frontier ... in 2016, and is projected to grow at a compound annual ... by 2025. The medical cannabis market is projected to grow at ... to an estimated $13.3 billion in 2025. These projections do not ...
(Date:3/22/2017)... -- TFS is pleased to announce the appointment of ... two global executive positions in Medical Affairs and Clinical Development. Dr. ... and will report to Dr. Montse BarcelĂł , Chief Operating ... ... of medical and scientific expertise gained across leading biopharmaceutical companies and ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 22, 2017 , ... Last year, 43 million ... US Department of Agriculture report. While excess dairy can be caused by several ... Lactose sensitivity is the inability to properly digest lactose, a sugar found in milk ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Carballo ... Jersey and the New York metropolitan region, is embarking on a cooperative charity ... families. , At present, more than two and a half million children in ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Vanderbeck Agency, a ... greater Nassau County region, is embarking on a combined charity effort with the Great ... For the last 25 years, the Great Neck Breast Cancer Coalition has worked to ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Jim Shortridge Agency, ... and business owners, is joining the Teen Recovery Solutions organization in a charity ... A growing number of Oklahoma teens and adolescents face problems from drugs, alcohol, ...
(Date:3/22/2017)... ... March 22, 2017 , ... The ... related services to families and business owners in the greater Nassau County area, ... & Lymphoma Society. , Every 3 minutes, someone in America is diagnosed with ...
Breaking Medicine News(10 mins):